The OTEZLA® international website
This site is intended for healthcare professionals outside the U.S.
The OTEZLA® international website
This site is intended for healthcare professionals outside the U.S.
|
OTEZLA 30 mg twice daily
|
||||
|---|---|---|---|---|
| Selected laboratory abnormalities | Weeks 0 to <52 (N = 721) n (%) |
Weeks > 52 to ≤104 (N = 520) n (%) |
Weeks > 104 to ≤156 (N = 443) n (%) |
Weeks > 156 to ≤208 (N = 401) n (%) |
| Alanine aminotransferase >3x ULN | 9/713 (1.3) | 2/518 (0.4) | 2/442 (0.5) | 1/401 (0.2) |
| Creatine > 1.7x ULN | 1/713 (0.1) | 0/518 (0.0) | 0/442 (0.0) | 1/401 (0.2) |
| Leukocytes <1.5, 109/L | 0/713 (0.0) | 0/517 (0.0) | 0/442 (0.0) | 0/401 (0.0) |
| Neutrophilis <1, 109/L | 2/713 (0.3) | 3/517 (0.0) | 2/442 (0.5) | 2/401 (0.5) |
| Platelets <75, 109/L | 0/713 (0.0) | 0/517 (0.0) | 1/441 (0.2) | 0/399 (0.0) |
| Hemoglobin, male <10.5 g/dL; females <8.5 g/dL | 5/713 (0.7) | 4/517 (0.8) | 5/442 (1.1) | 5/401 (1.2) |
aRepresents the number of patients with ≥1 occurrence of the abnormality at any time point/number of patients with ≥1 post-baseline value.
bRepresents the number of patients with ≥1 occurrence of the abnormality at any time point/number of patients with ≥1 post-baseline value.
cIncludes all patients who received apremilast during the exposure interval relative to the start of apremilast administration.
PALACE 1-3 pooled analysis.
ULN, upper limit of normal.
Discontinuation rates were generally low2-4
On November 21, 2019, Amgen acquired from Celgene Corporation the worldwide rights to Otezla® (apremilast).
Effective November 21, 2019, refer to the Amgen's Terms of Use relating to the access of Amgen websites, applications and digital services and Privacy Statement concerning the collection and use of your personal information.
For information collected by Celgene prior to November 21, 2019, refer to Celgene's Terms of Use and Privacy Policy.